News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Does Not Rule Out Sending Troops to Iran; Iran Closes Strait of Hormuz, Oil Prices Soar; Drone and Space Stocks Rise Collectively (2026/03/03)2Bitcoin slide slowing, but bear market still in play: Analysts3Research Report｜In-Depth Analysis and Market Cap of Opinion Labs (OPN)
Ethereum's Vitalik Buterin: build 'sanctuary tech,' forget emulating Apple or Google
The Block·2026/03/03 21:39
Anthropic's Tool Launch: A Strategic Boost for Technology Shares
101 finance·2026/03/03 21:27
A16z Crypto updates Jolt zkVM, challenges loose use of ‘ZK’ label
The Block·2026/03/03 21:15
Hasbro Relocates Headquarters: Savvy Financial Decision or Purposeful Organizational Shift?
101 finance·2026/03/03 21:03
Pi Network price prediction: $0.20 still in play as 3 signals align
AMBCrypto·2026/03/03 21:03
Mastercard and Visa strike agreements to boost stablecoins
101 finance·2026/03/03 21:00
Profit Realization and Guidance Adjustments: Navigating Expectation Gaps in Consumer Staples
101 finance·2026/03/03 20:57
XRP Under Pressure Despite 24 % Surge In Trading Volume
Cointribune·2026/03/03 20:57
38% of altcoins in critical zone according to CryptoQuant
Cointribune·2026/03/03 20:57
Trump Fears Iran’s Leadership Could Remain ‘Equally Problematic’ Following Conflict
101 finance·2026/03/03 20:51
Flash
21:43
Orion Marine Group recently released its 2026 financial guidance, which fully demonstrates the strong appeal of its end markets and its solid strategic positioning.The company is full of confidence in its future prospects. The new guidance not only outlines a clear path for growth, but also reflects the management's firm determination to seize market opportunities. This strategic plan will help the company continuously consolidate its advantageous position in a highly competitive industry.
21:42
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.The results of this trial mark a significant advancement in the safety profile of Ketamir-2, paving the way for its subsequent clinical development. The company emphasized that this discovery is expected to drive further exploration of the drug in therapeutic applications.
21:42
Moderna, Inc. (MRNA) has recently updated its financial outlook, announcing an adjustment of its expected cash and cash equivalents at the end of 2026 to a range of $4.5 billion to $5.0 billion.This revised forecast reflects the company's reassessment of its future cash flow situation.
News